Investigation of the Lactam Side Chain Length Necessary for Optimal Indenoisoquinoline Topoisomerase I Inhibition and Cytotoxicity in Human Cancer Cell Cultures
Abstract:Indenoisoquinolines with lactam substituents such as ethylamino, propylamino, and butylamino have previously demonstrated potent biological activity, but optimal length has never been established. In the present study, a series of simplified indenoisoquinoline analogues possessing a linker spacing of 0-12 carbon atoms between the lactam nitrogen and the terminal amino group have been prepared, determining that 2-4 atom lengths are optimal for topoisomerase I inhibition and cytotoxicity. Using these lengths, an… Show more
“…21 The selection of a three-carbon polymethylene linker between the lactam nitrogen and the side chain nitrogen in the final products is consistent with prior studies indicating that the optimal length is 2–4 atoms in comparable systems. 35 …”
Several indenoisoquinolines have shown promise as anticancer agents in clinical trials. Incorporation of a nitrogen atom into the indenoisoquinoline scaffold offers the possibility of favorably modulating ligand-binding site interactions, physicochemical properties, and biological activities. Four series of aza-A-ring indenoisoquinolines were synthesized in which the nitrogen atom was systematically rotated to all four possible locations. The resulting compounds were tested to establish the optimal nitrogen position for topoisomerase IB (Top1) enzyme poisoning activity and cytotoxicity to human cancer cells. The 4-aza compounds were the most likely to yield derivatives with high Top1 inhibitory activity. However, the cytotoxicity was more complicated, since the potency was influenced strongly by the side chains on the lactam nitrogen. The most cytotoxic azaindenoisoquinolines 45 and 46 had nitrogen in the 2- or 3-positions and a 3′-dimethylaminopropyl side chain, and they had MGM GI50 values that were slightly better than the corresponding indenoisoquinoline 64.
“…21 The selection of a three-carbon polymethylene linker between the lactam nitrogen and the side chain nitrogen in the final products is consistent with prior studies indicating that the optimal length is 2–4 atoms in comparable systems. 35 …”
Several indenoisoquinolines have shown promise as anticancer agents in clinical trials. Incorporation of a nitrogen atom into the indenoisoquinoline scaffold offers the possibility of favorably modulating ligand-binding site interactions, physicochemical properties, and biological activities. Four series of aza-A-ring indenoisoquinolines were synthesized in which the nitrogen atom was systematically rotated to all four possible locations. The resulting compounds were tested to establish the optimal nitrogen position for topoisomerase IB (Top1) enzyme poisoning activity and cytotoxicity to human cancer cells. The 4-aza compounds were the most likely to yield derivatives with high Top1 inhibitory activity. However, the cytotoxicity was more complicated, since the potency was influenced strongly by the side chains on the lactam nitrogen. The most cytotoxic azaindenoisoquinolines 45 and 46 had nitrogen in the 2- or 3-positions and a 3′-dimethylaminopropyl side chain, and they had MGM GI50 values that were slightly better than the corresponding indenoisoquinoline 64.
“…Indenoisoquinolines substituted with di- and polyamines are potent top1 inhibitors 31–32. It is known in general that di- and polyamine conjugates are effective “DNA-targeting” moieties for many classes of intercalating and anti-top1 compounds 31–35.…”
Section: Introductionmentioning
confidence: 99%
“…It is known in general that di- and polyamine conjugates are effective “DNA-targeting” moieties for many classes of intercalating and anti-top1 compounds 31–35. In 2007, Morrell et al determined that diamines with two- to four-carbon spacers were optimal substituents for bioactivity when placed on indenoisoquinolines 31. The question as to whether this SAR trend could also be applied to aromathecins served as a rationale for the synthesis of 14-[(aminoalkyl)-aminomethyl)aromathecins 53–63 .…”
The aromathecin topoisomerase I (top1) inhibitors offer promising scaffolds for the development of novel cancer chemotherapeutics. They are “composites” of the camptothecin and indenoisoquinoline top1 inhibitors. Interestingly, some structure-activity-relationship (SAR) overlap between the aromathecins and the indenoisoquinolines has been observed. For both classes, placement of certain polar groups in similar regions of the heteroaromatic system improves top1 inhibitory and antiproliferative activities. A series of water-soluble aromathecins substituted at position 14 with diaminoalkanes of various lengths has been prepared. These compounds all possess similar antiproliferative potency, but a general trend is observed: aromathecins with longer diaminoalkane substituents (> 6 carbons) possess lower anti-top1 activity than their smaller counterparts (2–4 carbons), presumably as a result of unfavorable hydrophobic interactions. This trend is also noted with the indenoisoquinolines, revealing additional SAR overlap that supports the hypothesis that there is a “universal” top1 inhibitor SAR.
“…In a continuation of our work, we report here the synthesis and biological activities of new series of 1,7-BZP and 1,8-BZP bearing at positions C2 and C1 on cycle A, respectively, different dialkylaminoalkyl substituents. These side chains, which mimick natural DNA ligands such as spermine and spermidine, were chosen due to the excellent results reported with such substituents in several related series including indén-oisoquinoléines [9], dibenzo[c,h] [1,6]naphthyridinones [10], camptothécine [11], and acronycine analogs [12].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.